<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11685">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022306</url>
  </required_header>
  <id_info>
    <org_study_id>0094</org_study_id>
    <nct_id>NCT02022306</nct_id>
  </id_info>
  <brief_title>TD-6450 SAD and MAD in Healthy Subjects</brief_title>
  <official_title>A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts, Parts A and B.  Part A is a single ascending dose (SAD)
      study in healthy subjects.  Part B is a multiple ascending dose (MAD) study in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days max</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 days max</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>28 days max</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>28 days max</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>28 days max</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect on AUC value</measure>
    <time_frame>15 days max</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure difference between fasted and fed doses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SAD TD-6450</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD TD-6450</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose (Part B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect of TD-6450</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Food effect will be assessed in Part A (SAD) of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-6450</intervention_name>
    <arm_group_label>SAD TD-6450</arm_group_label>
    <arm_group_label>MAD TD-6450</arm_group_label>
    <arm_group_label>Food effect of TD-6450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>SAD TD-6450</arm_group_label>
    <arm_group_label>MAD TD-6450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a female of non-childbearing potential or male, who is healthy,
             nonsmoking, and 18 to 60 years old, inclusive, at screening.  Females are considered
             to be of non childbearing potential if they have had a hysterectomy or tubal ligation
             (documentation required) or are postmenopausal (amenorrheic for at least 2 years)
             with a follicle stimulating hormone (FSH) level &gt;40 IU/L

          -  Subject has a body mass index 18 to 30 kg/m2, inclusive, and weighs at least 50 kg.

        Exclusion Criteria:

          -  Subject has evidence or history of clinically significant allergic (except for
             untreated, asymptomatic, seasonal allergies at time of dosing), hematological,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or
             neurological disease.

          -  Subject has an estimated creatinine clearance of &lt;90 mL/min at Screening or Day -1,
             calculated using the Cockcroft-Gault equation.

          -  Subject has participated in another clinical trial of an investigational drug (or
             medical device) within 60 days prior to Screening, or is currently participating in
             another trial of an investigational drug (or medical device).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger Kohler</last_name>
    <phone>650-808-6000</phone>
    <email>Rkohler@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Gonzalez</last_name>
      <phone>210-283-4541</phone>
    </contact>
    <investigator>
      <last_name>Emanuel DeNoia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
